A House subcommittee will hold a hearing Oct. 30 to discuss the safety of the U.S. drug supply chain after two major drugs were recalled due to potential carcinogens, according to Politico's Prescription Pulse newsletter.
Three generic blood pressure drugs — valsartan, losartan and irbesartan — as well as the heartburn drug Zantac were all recently recalled after potentially carcinogenic impurities were found in their active ingredients.
The active ingredient for the three blood pressure drugs was manufactured in China and its makerknew of the impurities, but failed to report the information, according to Politico.
The House Energy and Commerce Health Subcommittee will focus the meeting on the role of international drug companies in the U.S. drug supply chain.